```
     FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 11:42:39 ON 15 SEP 2005
                E FALK RUDOLF/AU
L1             82 S E2-7
L2              5 S ASCULAI SAMUEL/AU
L3             87 S L1 OR L2
L4             72 DUP REM L3 (15 DUPLICATES REMOVED)
L5          76962 S HYALURON?
L6             50 S L4 AND L5
L7        2121801 S CANCER
L8         578462 S CHEMOTHERAP?
L9         290158 S ANTIOXIDANT
L10         10501 S ANTI OXIDANT
L11        559201 S VITAMIN
L12         34839 S NSAID
L13         52479 S NONSTEROIDAL
L14         61698 S NON STEROIDAL
L15            28 S L6 AND (L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14
L16           175 S L5 AND L12
L17           166 S L16 NOT L15
L18           113 DUP REM L17 (53 DUPLICATES REMOVED)
L19           487 S L5 AND L8
L20           485 S L19 NOT L15
L21           343 DUP REM L20 (142 DUPLICATES REMOVED)
L22            23 S L21 AND (L9 OR L10 OR L11)
```

L15 ANSWER 1 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:380105 BIOSIS
DOCUMENT NUMBER: PREV200100380105
TITLE: Treatment of conditions and disease.
AUTHOR(S): **Falk, Rudolf Edgar** [Inventor, Reprint author]; Asculai, Samuel S. [Inventor]
CORPORATE SOURCE: Toronto, Canada
ASSIGNEE: Hyal Pharmaceutical Corporation, Mississauga, Canada
PATENT INFORMATION: US 6194392 20010227
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Feb. 27, 2001) Vol. 1243, No. 4. e-file. CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Aug 2001
Last Updated on STN: 19 Feb 2002
AB A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of **hyaluronic** acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of **hyaluronic** acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.

L15 ANSWER 2 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:273228 BIOSIS
DOCUMENT NUMBER: PREV200100273228
TITLE: Use of **hyaluronic** acid and a **NSAID** for the manufacture of a medicament for the treatment of mucosal diseases.
AUTHOR(S): Asculai, Samuel S. [Inventor, Reprint author]; **Falk, Rudolf E.** [Inventor]; Russell, Alan L. [Inventor]
CORPORATE SOURCE: Toronto, Canada
ASSIGNEE: SkyePharma PLC, London, UK
PATENT INFORMATION: US 6159955 20001212
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Dec. 12, 2000) Vol. 1241, No. 2. e-file. CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 6 Jun 2001
Last Updated on STN: 19 Feb 2002
AB The use of an effective amount of a composition comprising an N.S.A.I.D. and a form of **hyaluronic** acid selected from **hyaluronic** acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof for mucous membrane trauma, disease, and/or pain relief.

L15 ANSWER 3 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:253177 BIOSIS
DOCUMENT NUMBER: PREV200100253177
TITLE: Formulations containing **hyaluronic** acid.
AUTHOR(S): **Falk, Rudolf Edger** [Inventor, Reprint author]; Asculai, Samuel Simon [Inventor]; Hochman, David [Inventor]; Purschke, Don [Inventor]; Klein, Ehud Shmuel [Inventor]; Harper, David William [Inventor]
CORPORATE SOURCE: Toronto, Canada
ASSIGNEE: Hyal Pharmaceutical Corporation, Mississauga, Canada
PATENT INFORMATION: US 6136793 20001024
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 24, 2000) Vol. 1239, No. 4. e-file. CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 23 May 2001
Last Updated on STN: 19 Feb 2002
AB A method of treating a disease or condition comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of **hyaluronic** acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology

of the disease or condition to be treated.

L15 ANSWER 4 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2001:204884 BIOSIS
DOCUMENT NUMBER: PREV200100204884
TITLE: Formulations containing **hyaluronic** acid.
AUTHOR(S): **Falk, Rudolf Edgar** [Inventor, Reprint author]; Asculai, Samuel Simon [Inventor]; Klein, Ehud Shmuel [Inventor]; Harper, David W. [Inventor]; Hochman, David [Inventor]; Purschke, Don [Inventor]
CORPORATE SOURCE: Toronto, Canada
ASSIGNEE: Hyal Pharmaceutical Corp., Canada
PATENT INFORMATION: US 6114314 20000905
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 5, 2000) Vol. 1238, No. 1. e-file. CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Apr 2001
Last Updated on STN: 18 Feb 2002

AB Topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) systemic independent acting, combinations and formulations which employ, combine, or incorporate a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis together with an amount of **hyaluronic** acid and/or salts thereof (for example the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub units of **hyaluronic** acid to treat a disease and condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic **cancer** of the breast to the skin, primary and metastatic melanoma in the skin, genital warts cervical **cancer**, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women and remain in the skin for a prolonged period of time.

L15 ANSWER 5 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2000:341677 BIOSIS
DOCUMENT NUMBER: PREV200000341677
TITLE: Topical composition containing **hyaluronic** acid and **nsaids**.
AUTHOR(S): **Falk, Rudolf Edgar** [Inventor, Reprint author]; Asculai, Samuel Simon [Inventor]
CORPORATE SOURCE: Toronto, Canada
ASSIGNEE: Hyal Pharmaceutical Corporation, Missisauga, Canada
PATENT INFORMATION: US 6017900 20000125
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jan. 25, 2000) Vol. 1230, No. 4. e-file. CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Aug 2000
Last Updated on STN: 7 Jan 2002

AB A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology or trauma of skin or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic dosage amount of a drug for the treatment of the disease or condition of the skin or exposed tissue at the site of the pathology or trauma and an effective non-toxic dosage amount of **hyaluronic** acid or salts thereof or homologues, analogues, derivatives, complexes, esters, fragments, or sub-units of **hyaluronic** acid to transport the drug to the site of the pathology or trauma of the disease or condition.

L15 ANSWER 6 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2000:289979 BIOSIS
DOCUMENT NUMBER: PREV200000289979
TITLE: Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof.
AUTHOR(S): Asculai, Samuel Simon [Inventor, Reprint author]; Russell, Alan Lawrence [Inventor]; **Falk, Rudolf Edgar**

[Inventor]
CORPORATE SOURCE: Mississauga, Canada
ASSIGNEE: Hyal Pharmaceutical Corporation
PATENT INFORMATION: US 5972906 19991026
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 26, 1999) Vol. 1227, No. 4. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 6 Jul 2000
Last Updated on STN: 7 Jan 2002

AB A method for the treatment of mucous membrane trauma disease or condition for the relief of pain associated therewith comprising administering topically an effective amount of a composition comprising an N.S.A.I.D. and a form of **hyaluronic** acid selected from **hyaluronic** acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof.

L15 ANSWER 7 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:494980 BIOSIS
DOCUMENT NUMBER: PREV199900494980
TITLE: Treatment of disease and conditions.
AUTHOR(S): **Falk, Rudolf Edgar** [Inventor, Reprint author]; Asculai, Samuel Simon [Inventor]
CORPORATE SOURCE: University of Toronto, Toronto, Canada
ASSIGNEE: Hyal Pharmaceutical Corporation
PATENT INFORMATION: US 5914322 19990622
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jun. 22, 1999) Vol. 1223, No. 4. print.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Nov 1999
Last Updated on STN: 16 Nov 1999

L15 ANSWER 8 OF 28 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:383189 BIOSIS
DOCUMENT NUMBER: PREV199900383189
TITLE: Topical composition containing **hyaluronic** acid and **NSAIDS**.
AUTHOR(S): **Falk, Rudolf Edgar** [Inventor, Reprint author]; Asculai, Samuel Simon [Inventor]
CORPORATE SOURCE: University of Toronto, Toronto, Canada
ASSIGNEE: Hyal Pharmaceutical Corporation
PATENT INFORMATION: US 5910489 19990608
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jun.08, 1999) Vol. 1223, No. 2. print.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Sep 1999
Last Updated on STN: 13 Sep 1999

L15 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:789053 CAPLUS
DOCUMENT NUMBER: 130:29256
TITLE: Method of administration for a therapeutic agent utilizing suitable forms of **hyaluronic** acid and combinations with electroporation
INVENTOR(S): **Falk, Rudolf E.**; Asculai, Samuel S.
PATENT ASSIGNEE(S): Hyal Pharmaceutical Corp., Can.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9852613	A2	19981126	WO 1998-CA449	19980511
WO 9852613	A3	19990225		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2205692	AA	19981116	CA 1997-2205692		19970516
AU 9873287	A1	19981211	AU 1998-73287		19980511
PRIORITY APPLN. INFO.:			CA 1997-2205692	A	19970516
			WO 1998-CA449	W	19980511

AB A method of administration for a therapeutic agent is disclosed which uses suitable forms of **hyaluronic** acid in combination with elec. assisted delivery methods, e.g. electrotransport or electroporation. The formulations of the invention include a therapeutic agent and sufficient **hyaluronic** acid to facilitate the therapeutic agent's penetration through the tissue (including scar tissue), at the site to be treated, through the cell membranes into the individual cells to be treated.

L15 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:735041 CAPLUS
DOCUMENT NUMBER: 129:339871
TITLE: **Hyaluronic** acid and its salts inhibit arterial restenosis
INVENTOR(S): **Falk, Rudolf Edgar**; Turley, Eva Anne; Asculai, Samuel Simon
PATENT ASSIGNEE(S): Hyal Pharmaceutical Corporation, Can.
SOURCE: U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 675,908.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5834444	A	19981110	US 1993-125398	19930923
CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
US 5639738	A	19970617	US 1992-838675	19920221
US 5827834	A	19981027	US 1994-286263	19940805
US 6114314	A	20000905	US 1994-352697	19941201
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
US 5990095	A	19991123	US 1995-448503	19950726
US 6194392	B1	20010227	US 1995-460978	19950807
CA 2268476	AA	19980430	CA 1996-2268476	19961018
WO 9817320	A1	19980430	WO 1996-CA700	19961018
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
US 2002077314	A1	20020620	US 1997-996470	19971222
US 6852708	B2	20050208		
US 2003036525	A1	20030220	US 2002-234355	20020904
PRIORITY APPLN. INFO.:			US 1991-675908	A2 19910703
			US 1992-838674	B2 19920221
			US 1992-838675	A2 19920221
			US 1992-952095	B2 19920928
			CA 1989-612307	A 19890921
			WO 1990-CA306	W 19900918
			CS 1990-4598	A 19900921
			CA 1992-2061566	A 19920220
			US 1993-125398	A2 19930923
			WO 1994-CA188	W 19940325
			US 1995-448503	A1 19950726

WO 1996-CA700	A	19961018
US 1997-860696	A1	19970616

AB A method is provided of preventing arterial restenosis of an animal after the arteries have been traumatized. The method comprises the administration of a therapeutically effective non-toxic amount of **hyaluronic** acid and/or pharmaceutically acceptable salts thereof to the animal to prevent narrowing of the arteries. The form of **hyaluronic** acid is selected from **hyaluronic** acid and pharmaceutically acceptable salts thereof having a mol. weight less than 750,000 daltons. **Hyaluronan** treatment of rabbits just prior to their injury abolished adherence of white cells to endothelium resulting in tissue that appeared intact as detected by hitol. criteria.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:653540 CAPLUS

DOCUMENT NUMBER: 129:255000

TITLE: Clearing of atherosclerosis with pharmaceutical composition containing a chelating agent, a **nonsteroidal** antiinflammatory drug, an **antioxidant**, and **hyaluronic** acid or a **hyaluronic** acid salt or derivative

INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel Simon

PATENT ASSIGNEE(S): Hyal Pharmaceutical Corporation, Can.

SOURCE: U.S., 5 pp., Cont.-in-part of U.S. Ser. No. 675,908.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 24

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5817642	A	19981006	US 1995-464769	19950815
CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
CA 2122551	AA	19951030	CA 1994-2122551	19940429
US 5827834	A	19981027	US 1994-286263	19940805
WO 9529683	A1	19951109	WO 1995-CA243	19950427
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
US 6194392	B1	20010227	US 1995-460978	19950807
CA 2268476	AA	19980430	CA 1996-2268476	19961018
WO 9817320	A1	19980430	WO 1996-CA700	19961018
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
US 2003036525	A1	20030220	US 2002-234355	20020904

PRIORITY APPLN. INFO.:

US 1991-675908	A2	19910703
CA 1994-2122551	A	19940429
WO 1995-CA243	W	19950427
CA 1989-612307	A	19890921
WO 1990-CA306	W	19900918
CS 1990-4598	A	19900921

	WO 1996-CA700	A	19961018
	US 1997-860696	A1	19970616

AB A method of clearing atherosclerosis comprises administering to a patient at least one dosage amount of a pharmaceutical composition comprising an effective nontoxic amount of each of a chelating agent, a **nonsteroidal** antiinflammatory drug (**NSAID**), an **anti-oxidant** and a form of **hyaluronic** acid, selected from **hyaluronic** acid, salts thereof, homologs, analogs, derivs., esters, complexes, fragments and subunits.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:740122 CAPLUS
DOCUMENT NUMBER: 128:7341
TITLE: Use of forms of **hyaluronic** acid for the treatment of **cancer**
INVENTOR(S): **Falk, Rudolf Edgar**
PATENT ASSIGNEE(S): Hyal Pharmaceutical Corporation, Can.; Falk, Rudolf Edgar
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740841	A1	19971106	WO 1997-CA283	19970428
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2175282	AA	19971030	CA 1996-2175282	19960429
ZA 9703622	A	19971125	ZA 1997-3622	19970425
AU 9725644	A1	19971119	AU 1997-25644	19970428

PRIORITY APPLN. INFO.:	CA 1996-2175282	A	19960429
	WO 1997-CA283	W	19970428

AB A method is provided for the treatment of **cancer** comprising administering orally or systemically (i.v. preferably) of an effective dosage amount of a form of **hyaluronic** acid selected from the group consisting of **hyaluronic** acid and pharmaceutically acceptable salts thereof as the only therapeutic agent, in a diluent, in such amts. and over such period of time to permit the successful treatment of **cancer**. Clin results are given.

L15 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:436579 CAPLUS
DOCUMENT NUMBER: 127:99842
TITLE: Treatment of basal cell carcinoma and actinic keratosis employing **hyaluronic** acid and **NSAIDs**
INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel Simon
PATENT ASSIGNEE(S): Hyal Pharmaceutical Corp., Can.
SOURCE: U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 675,908.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5639738	A	19970617	US 1992-838675	19920221
CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
CA 2061566	AA	19930821	CA 1992-2061566	19920220
CA 2061566	C	20020709		
US 5792753	A	19980811	US 1993-18508	19930217
US 6103704	A	20000815	US 1993-18754	19930217
WO 9407505	A1	19940414	WO 1993-CA388	19930922

W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5834444	A	19981110	US 1993-125398	19930923	
WO 9526193	A1	19951005	WO 1994-CA188	19940325	

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, US, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5614506	A	19970325	US 1994-285764	19940803
US 5827834	A	19981027	US 1994-286263	19940805
US 5910489	A	19990608	US 1994-290848	19940819
US 6022866	A	20000208	US 1995-403766	19950324
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
US 5914322	A	19990622	US 1995-466774	19950606
US 5962433	A	19991005	US 1995-466778	19950606
US 6017900	A	20000125	US 1995-466775	19950606
US 5972906	A	19991026	US 1995-503919	19950719
US 5990095	A	19991123	US 1995-448503	19950726
US 5824658	A	19981020	US 1995-468329	19950807
US 6194392	B1	20010227	US 1995-460978	19950807
CA 2268476	AA	19980430	CA 1996-2268476	19961018
WO 9817320	A1	19980430	WO 1996-CA700	19961018

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		

R: DE, FR, GB, IT, SE

NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
AU 9742732	A1	19980115	AU 1997-42732	19971020
US 2002077314	A1	20020620	US 1997-996470	19971222
US 6852708	B2	20050208		
AU 768058	B2	20031127	AU 2000-42729	20000628
US 2003036525	A1	20030220	US 2002-234355	20020904

PRIORITY APPLN. INFO.:

US 1991-675908	A2	19910703
CA 1992-2061566	A	19920220
CA 1989-612307	A	19890921
WO 1990-CA306	W	19900918
CS 1990-4598	A	19900921
CA 1992-2061703	A	19920220
US 1992-838674	A2	19920221
US 1992-838675	A2	19920221
CA 1992-2079205	A	19920925
US 1992-952095	A2	19920928
US 1993-18508	A2	19930217
US 1993-18754	A2	19930217
WO 1993-CA388	W	19930922
US 1993-125398	A2	19930923
WO 1994-CA188	W	19940325
US 1994-285764	A2	19940803
US 1994-290848	A3	19940819
US 1994-290840	A2	19941027
US 1995-448503	A1	19950726
WO 1996-CA700	A	19961018
US 1997-860696	A1	19970616
AU 1997-42732	A3	19971020

AB A method of treating a mammal for a condition of the skin or exposed tissue selected from the group consisting of basal cell carcinoma and actinic keratosis is provided. The method consists essentially of topically administering to the site of the condition, more than once per day over a period of days sufficient to treat the condition, a non-toxic

effective dosage amount of a composition consisting essentially of (a) a **non-steroidal** anti-inflammatory drug (**NSAID**) in an amount sufficient to block prostaglandin synthesis, (b) **hyaluronic** acid or a pharmaceutically acceptable salt thereof in an amount effective to transport said **NSAID** into the skin or exposed tissue at the site of the condition. The concentration of the **hyaluronic** add or salt thereof is between 1-3% by weight of the composition The mol. weight of the **hyaluronic** acid or salt thereof is between 150,000 and 750,000 Daltons. A pharmaceutical excipient suitable for topical application is included. The **NSAID** in the composition may be diclofenac sodium.

L15 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:289979 CAPLUS
DOCUMENT NUMBER: 126:259170
TITLE: Treatment of mucous membrane disease, trauma or condition and for the relief of pain
INVENTOR(S): Asculai, Samuel Simon; **Falk, Rudolf Edgar**; Russell, Alan L.
PATENT ASSIGNEE(S): Hyal Pharmaceutical Corporation, Can.
SOURCE: Can. Pat. Appl., 45 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2154103	AA	19970119	CA 1995-2154103	19950718
CA 2154103	C	19980224		
WO 9703699	A1	19970206	WO 1996-CA488	19960718
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
AU 9663519	A1	19970218	AU 1996-63519	19960718
AU 719257	B2	20000504		
EP 839052	A1	19980506	EP 1996-922722	19960718
EP 839052	B1	20020508		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11514967	T2	19991221	JP 1996-506120	19960718
NZ 312073	A	20000228	NZ 1996-312073	19960718
AT 217197	E	20020515	AT 1996-922722	19960718
ES 2176468	T3	20021201	ES 1996-922722	19960718
US 6159955	A	20001212	US 1997-981602	19971224

PRIORITY APPLN. INFO.: CA 1995-2154103 A 19950718
WO 1996-CA488 W 19960718

AB The use of an effective amount of a composition comprising an N.S.A.I.D. and a form of **hyaluronic** acid selected from **hyaluronic** acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof for mucous membrane trauma, disease, and/or pain relief. Clin. data are given for compns. containing **hyaluronic** acid and diclofenac Na.

L15 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:153570 CAPLUS
DOCUMENT NUMBER: 124:194320
TITLE: **Non-steroidal** anti-inflammatory agents and **hyaluronic** acid derivatives for inhibition, control and regression of angiogenesis
INVENTOR(S): Willoughby, Derek A.; Alam, Chandan; Asculai, Samuel S.; **Falk, Rudolf E.**; Harper, David W.
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: Can. Pat. Appl., 53 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

CA 2121454	AA	19951016	CA 1994-2121454	19940415
PRIORITY APPLN. INFO.:			CA 1994-2121454	19940415

AB **Non-steroidal** anti-inflammatory agents, and **hyaluronic** acid (I) and/or salts thereof and/or homologs, analogs, derivs., complexes, esters, fragments, and subunits of I, are used for the manufacture of a pharmaceutical composition for inhibition, controlling and/or regressing angiogenesis. Topical application of of 1% sodium **hyaluronate** and 6 mg/kg diclofenac acted synergistically and inhibited angiogenesis in rats.

L15 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:145026 CAPLUS
DOCUMENT NUMBER: 124:165261
TITLE: Use of **hyaluronic** acid and forms to prevent arterial restenosis
INVENTOR(S): **Falk, Rudolf E.**; Asculai, Samuel S.; Turley, Eva A.
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: Can. Pat. Appl., 86 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2120045	AA	19950926	CA 1994-2120045	19940325
CA 2120045	C	20000530		
PRIORITY APPLN. INFO.:			CA 1994-2120045	19940325

AB For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of **hyaluronic** acid and/or salts and/or homologs, analogs, derivs., complexes, esters, fragments, and subunits of **hyaluronic** acid to the animal to prevent narrowing of the tubular walls.

L15 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:99453 CAPLUS
DOCUMENT NUMBER: 124:127136
TITLE: Pharmaceutical composition comprising **hyaluronic** acid for the clearing of arteriosclerosis
INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel Simon
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9529683	A1	19951109	WO 1995-CA243	19950427
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
CA 2122551	AA	19951030	CA 1994-2122551	19940429
US 5827834	A	19981027	US 1994-286263	19940805
AU 9523008	A1	19951129	AU 1995-23008	19950427
EP 758246	A1	19970219	EP 1995-916533	19950427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09512537	T2	19971216	JP 1995-527900	19950427
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
US 6194392	B1	20010227	US 1995-460978	19950807
US 5817642	A	19981006	US 1995-464769	19950815
CA 2268476	AA	19980430	CA 1996-2268476	19961018

WO 9817320		A1	19980430	WO 1996-CA700	19961018
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9672721		A1	19980515	AU 1996-72721	19961018
AU 739701		B2	20011018		
EP 952855		A1	19991103	EP 1996-934250	19961018
EP 952855		B1	20050727		
R:	DE, FR, GB, IT, SE				
NZ 335259		A	20001222	NZ 1996-335259	19961018
ZA 9608847		A	19970527	ZA 1996-8847	19961022
US 6475795		B1	20021105	US 1997-860696	19970616
US 2003036525		A1	20030220	US 2002-234355	20020904
PRIORITY APPLN. INFO.:				US 1991-675908	A2 19910703
				CA 1994-2122551	A 19940429
				CA 1989-612307	A 19890921
				WO 1990-CA306	W 19900918
				CS 1990-4598	A 19900921
				WO 1995-CA243	W 19950427
				WO 1996-CA700	A 19961018
				US 1997-860696	A1 19970616

AB A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a **non-steroidal** anti-inflammatory drug (**NSAID**), an **anti-oxidant** and a form of **hyaluronic** acid, selected from **hyaluronic** acid, salts thereof, homologs, analogs, derivs., esters, complexes, fragments and subunits. An i.v. solution contained EDTA 3, sodium ascorbate 12.5 g, diclofenac 15 , and sodium **hyaluronate** 50 mg. The efficacy of composition was in treatment of atherosclerotic patients was shown.

L15 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:43012 CAPLUS
DOCUMENT NUMBER: 124:66655
TITLE: Pharmaceutical compositions comprising anti-**cancer** drugs and **hyaluronic** acid for treatment of **cancer** and metastasis prevention
INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel Simon
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9530423	A2	19951116	WO 1995-CA259	19950428
WO 9530423	A3	19951221		
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA			
RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
CA 2122519	AA	19951030	CA 1994-2122519	19940429
CA 2122519	C	20010220		
US 5827834	A	19981027	US 1994-286263	19940805
AU 9524023	A1	19951129	AU 1995-24023	19950428
AU 696373	B2	19980910		
EP 760667	A1	19970312	EP 1995-917846	19950428
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
HU 75868	A2	19970528	HU 1996-2965	19950428
CN 1151118	A	19970604	CN 1995-193689	19950428
JP 09512797	T2	19971222	JP 1995-528564	19950428

RU 2162327	C2	20010127	RU 1996-122884		19950428
US 5811410	A	19980922	US 1995-465335		19950605
US 5830882	A	19981103	US 1995-462615		19950605
US 5852002	A	19981222	US 1995-462147		19950605
US 6194392	B1	20010227	US 1995-460978		19950807
CA 2268476	AA	19980430	CA 1996-2268476		19961018
WO 9817320	A1	19980430	WO 1996-CA700		19961018
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9672721	A1	19980515	AU 1996-72721		19961018
AU 739701	B2	20011018			
EP 952855	A1	19991103	EP 1996-934250		19961018
EP 952855	B1	20050727			
R: DE, FR, GB, IT, SE					
NZ 335259	A	20001222	NZ 1996-335259		19961018
ZA 9608847	A	19970527	ZA 1996-8847		19961022
US 6475795	B1	20021105	US 1997-860696		19970616
US 2003036525	A1	20030220	US 2002-234355		20020904
PRIORITY APPLN. INFO.:			US 1991-675908	A2	19910703
			CA 1994-2122519	A	19940429
			CA 1989-612307	A	19890921
			WO 1990-CA306	W	19900918
			CS 1990-4598	A	19900921
			WO 1995-CA259	W	19950428
			WO 1996-CA700	A	19961018
			US 1997-860696	A1	19970616

AB A new method for the treatment of **cancer** in a human particularly malignant tumors, for example those in a breast or breasts, comprising the steps of: (1) directly injecting into the tumor a dosage amount of a pharmaceutical composition comprising an effective amount of an anti-**cancer** drug and/or drug suitable for use to treat **cancer** , such as mitoxantrone, and an effective amount of a form of **hyaluronic** acid or pharmaceutically acceptable salts thereof, such as sodium **hyaluronate** having a mol. weight of less than 750,000 daltons, sterile water; and (2) administering systemically, preferably i.v., a dosage amount of a pharmaceutical composition comprising: (a) an effective amount of a form of **hyaluronic** acid or pharmaceutically acceptable salts thereof; (b) a drug selected from the group comprising: a **non-steroidal** anti-inflammatory drug, an anti-**cancer** drug, and a drug suitable for use to treat **cancer** and combination thereof optionally together with an **antioxidant** such as **vitamin** C. A patient with breast **cancer** was treated with **non-steroidal** anti-inflammatory drugs, sodium ascorbate **hyaluronic** acid i.v. The patient was also injected with mitoxantrone/**hyaluronic** acid on 4 occasions. Completed response with total regression of local tumor was observed and patient did not develop any metastases. Schedules for patients dosages are given.

L15 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:967290 CAPLUS
DOCUMENT NUMBER: 124:789
TITLE: Use of **hyaluronic** acid and forms thereof to prevent arterial restenosis
INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel Simon; Turley, Eva Anne
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526193	A1	19951005	WO 1994-CA188	19940325
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, US, US, UZ, VN				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
US 5639738	A	19970617	US 1992-838675	19920221
AU 9464222	A1	19951017	AU 1994-64222	19940325
US 5827834	A	19981027	US 1994-286263	19940805
US 6114314	A	20000905	US 1994-352697	19941201
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
US 5990095	A	19991123	US 1995-448503	19950726
US 6194392	B1	20010227	US 1995-460978	19950807
CA 2268476	AA	19980430	CA 1996-2268476	19961018
WO 9817320	A1	19980430	WO 1996-CA700	19961018
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
US 2003036525	A1	20030220	US 2002-234355	20020904

PRIORITY APPLN. INFO.:	US 1991-675908	A2 19910703
	US 1992-838674	A2 19920221
	US 1992-838675	A2 19920221
	US 1992-952095	A2 19920928
	CA 1989-612307	A 19890921
	WO 1990-CA306	W 19900918
	CS 1990-4598	A 19900921
	CA 1992-2061566	A 19920220
	US 1993-125398	A2 19930923
	WO 1994-CA188	W 19940325
	WO 1996-CA700	A 19961018
	US 1997-860696	A1 19970616

AB For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, a therapeutically effective nontoxic amount of **hyaluronic** acid, and/or a salt, homolog, analog, derivative, complex, ester, fragment, or subunit thereof, is administered to the animal to prevent narrowing of the tubular walls, e.g. arterial walls subjected to balloon angioplasty.

L15 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:705578 CAPLUS
DOCUMENT NUMBER: 123:93340
TITLE: **Hyaluronic** acid and forms to prevent arterial restenosis
INVENTOR(S): **Falk, Rudolf E.**; Asculai, Samuel S.; Turley, Eva A.
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: Can. Pat. Appl., 42 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2106695	AA	19950323	CA 1993-2106695	19930922
CA 2106695	C	20000118		

PRIORITY APPLN. INFO.: CA 1993-2106695 19930922

AB A method for preventing arterial restenosis after trauma (e.g during balloon angioplasty) comprises i.v. administration of a therapeutically effective nontoxic amount of **hyaluronic** acid and/or its salts and/or homologs, analogs, derivs., complexes, esters, fragments, and subunits of **hyaluronic** acid and an agent selected from a

non-steroidal anti-inflammatory drug, restenosis inhibiting drug, **vitamin** C, **antioxidant**, and free radical scavenger.

L15 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:524394 CAPLUS
DOCUMENT NUMBER: 122:256405
TITLE: Prevention and control of **cancer** with antiinflammatory agents and **hyaluronic** acid
INVENTOR(S): **Falk, Rudolf E.**; Asculai, Samuel S.
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: Can. Pat. Appl., 213 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2097892	AA	19941207	CA 1993-2097892	19930607
PRIORITY APPLN. INFO.:			CA 1993-2097892	19930607

AB A method of conditioning the immune system in humans to resist the formation of ≥1 cancerous tissue types comprises administering a nontoxic dosage amount of a composition comprising pharmaceutical excipients, a **nonsteroidal** antiinflammatory agent, **hyaluronic** acid and/or salts or derivs. thereof, and optionally **vitamin** C. Thus, repeated topical application of a 2.5% Na **hyaluronate** gel containing 3% Na diclofenac to basal cell carcinomas of the skin resulted in regression and disappearance of the lesions.

L15 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:316085 CAPLUS
DOCUMENT NUMBER: 122:89434
TITLE: Formulations containing **hyaluronic** acid for facilitation of drug transport
INVENTOR(S): **Falk, Rudolf E.**; Asculai, Samuel S.; Klein, Ehud S.; Harper, David W.; Hochman, David; Purschke, Don
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: Can. Pat. Appl., 117 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2089621	AA	19940817	CA 1993-2089621	19930216
PRIORITY APPLN. INFO.:			CA 1993-2089621	19930216

AB Pharmaceutical compns. are provided from which effective nontoxic (to the patient) dosage amts. may be taken and applied to the skin and/or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective nontoxic dosage amount of a drug to treat a disease and/or condition of the skin and/or exposed tissue, and an effective nontoxic dosage amount of **hyaluronic** acid or its salts, homologs, analogs, derivs., complexes, esters, fragments, and/or subunits sufficient to facilitate or cause transport of the drug to a site in the skin, including epidermis or exposed tissue, resulting in its accumulation for a prolonged period of time. Thus, a gel containing glycerin 150, PhCH2OH 90, diclofenac Na 90, Na **hyaluronate** 75 g, and water 2795 mL, applied topically to cutaneous basal cell carcinoma several times a day for several wk, caused disappearance of the carcinoma.

L15 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:309098 CAPLUS
DOCUMENT NUMBER: 122:64428
TITLE: Treatment of disease employing **hyaluronic** acid to facilitate transport of **nonsteroidal** antiinflammatory drugs (**NSAIDs**)
INVENTOR(S): **Falk, Rudolf E.**; Asculai, Samuel S.
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: Can. Pat. Appl., 116 pp.
CODEN: CPXXEB

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2089635	AA	19940817	CA 1993-2089635	19930216
PRIORITY APPLN. INFO.:			CA 1993-2089635	19930216

AB A pharmaceutical composition comprises a plurality of effective nontoxic dosage amts. of a **NSAID** for topical administration to the site of pathol. and/or trauma of skin and/or exposed tissue of a human patient, combined with an effective nontoxic dosage amount of **hyaluronic** acid and/or its salts, homologs, analogs, derivs., complexes, esters, fragments, and/or subunits to facilitate or cause transport of the drug to the site of the pathol. and/or trauma. Thus, application of a formulation containing glycerin 150, PhCH2OH 90, diclofenac Na 90, Na **hyaluronate** 75 g, and water 2795 mL to an actinic keratosis lesion 3 times daily for 7 days resulted in complete resolution of the lesion.

L15 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:275006 CAPLUS
DOCUMENT NUMBER: 122:38842
TITLE: Compositions for inhibition control and regression of angiogenesis containing **hyaluronic** acid and **NSAID**
INVENTOR(S): Willoughby, Derek A.; Alam, Chandan; Asculai, Samuel Simon; **Falk, Rudolf Edgar**; Harper, David William
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9423725	A1	19941027	WO 1994-CA207	19940415
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2094203	AA	19941017	CA 1993-2094203	19930416
IL 109293	A1	19990126	IL 1994-109293	19940411
AU 9465616	A1	19941108	AU 1994-65616	19940415
AU 694113	B2	19980716		
ZA 9402597	A	19950208	ZA 1994-2597	19940415
BR 9405781	A	19960116	BR 1994-5781	19940415
EP 695187	A1	19960207	EP 1994-913464	19940415
EP 695187	B1	20021030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08508505	T2	19960910	JP 1994-522574	19940415
HU 74462	A2	19961230	HU 1995-113	19940415
AT 226827	E	20021115	AT 1994-913464	19940415
CN 1123005	A	19960522	CN 1994-192096	19940515
US 5847002	A	19981208	US 1995-461123	19950605
NO 9504073	A	19951204	NO 1995-4073	19951013
FI 9504914	A	19951106	FI 1995-4914	19951016
AU 9869941	A1	19980723	AU 1998-69941	19980605
PRIORITY APPLN. INFO.:			CA 1993-2094203 A	19930416
			WO 1994-CA207 W	19940415
			US 1995-448504 A3	19950605

AB The use of: (a) a **non-steroidal** anti-inflammatory agent, and (b) **hyaluronic** acid and/or salts thereof and/or homologous, analogs, derivs., complexes, esters, fragments, and subunits of **hyaluronic** acid, in the manufacture of pharmaceutical composition of inhibiting, controlling and/or regressing angiogenesis in a therapy wherein dosage amts. taken form the composition each comprise: (1) a therapeutically effective amount of component (a); and (2) a therapeutically effective amount of the **hyaluronic** acid and/or salts there of and/or homologous, analogs, derivs., complexes, esters, fragments, and sub-units of **hyaluronic** acid, the pharmaceutical composition being characterized in that for each dose amount taken from the pharmaceutical

composition, the amount of components (a) and (b) inhibit, control and/or regress angiogenesis.

L15 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:315827 CAPLUS
DOCUMENT NUMBER: 120:315827
TITLE: Use of **hyaluronic** acid and forms thereof to prevent arterial restenosis
INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel Simon; Turley, Eva Anne
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407505	A1	19940414	WO 1993-CA388	19930922
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CZ 288292	B6	20010516	CZ 1990-4598	19900921
US 6069135	A	20000530	US 1991-675908	19910703
US 5639738	A	19970617	US 1992-838675	19920221
CA 2079205	AA	19940326	CA 1992-2079205	19920925
CA 2079205	C	19980210		
EP 661981	A1	19950712	EP 1993-920624	19930922
EP 661981	B1	19960807		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AU 670117	B2	19960704	AU 1993-48126	19930922
AU 9348126	A1	19940426		
JP 08506797	T2	19960723	JP 1994-508543	19930922
AT 141054	E	19960815	AT 1993-920624	19930922
HU 73637	A2	19960828	HU 1995-857	19930922
ES 2091031	T3	19961016	ES 1993-920624	19930922
BR 9307221	A	19990727	BR 1993-7221	19930922
NZ 299942	A	20010525	NZ 1993-299942	19930922
CZ 288986	B6	20011017	CZ 1995-662	19930922
ZA 9307068	A	19940418	ZA 1993-7068	19930924
CN 1092654	A	19940928	CN 1993-119844	19930924
CN 1057908	B	20001101		
US 5827834	A	19981027	US 1994-286263	19940805
US 6114314	A	20000905	US 1994-352697	19941201
NO 9501122	A	19950323	NO 1995-1122	19950323
NO 309457	B1	20010205		
US 6022866	A	20000208	US 1995-403766	19950324
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
IN 181288	A	19980502	IN 1995-CA669	19950613
IN 181289	A	19980502	IN 1995-CA670	19950613
IN 182376	A	19990403	IN 1995-CA671	19950613
US 6194392	B1	20010227	US 1995-460978	19950807
AU 9670224	A1	19961219	AU 1996-70224	19961016
AU 702929	B2	19990311		
CA 2268476	AA	19980430	CA 1996-2268476	19961018
WO 9817320	A1	19980430	WO 1996-CA700	19961018
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018

ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
US 2003036525	A1	20030220	US 2002-234355	20020904

PRIORITY APPLN. INFO.:

US 1991-675908	A2	19910703
US 1992-838674	A2	19920221
US 1992-838675	A2	19920221
CA 1992-2079205	A	19920925
US 1992-952095	A2	19920928
CA 1989-612307	A	19890921
WO 1990-CA306	W	19900918
CS 1990-4598	A	19900921
CA 1992-2061566	A	19920220
IN 1993-CA554	A1	19930922
NZ 1993-255978	A1	19930922
WO 1993-CA388	W	19930922
US 1994-285764	A2	19940803
WO 1996-CA700	A	19961018
US 1997-860696	A1	19970616

AB For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, a therapeutically effective nontoxic amount of **hyaluronic** acid and/or salts thereof and/or homologs, analogs, derivs., complexes, esters, fragments, and subunits thereof is administered. Results are presented which demonstrate that profound changes in the expression of **hyaluronic** acid and the receptor for **hyaluronic** acid-mediated motility occur after in vivo vascular injury and that the receptor-**hyaluronic** acid interaction is required for inflammatory cell chemotaxis and smooth muscle cell migration in vitro.

L15 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:641409 CAPLUS
DOCUMENT NUMBER: 119:241409
TITLE: Topical composition containing **hyaluronic** acid and **nonsteroidal** inflammation inhibitors for treatment of skin diseases.
INVENTOR(S): **Falk, Rudolf Edgar;** Asculai, Samuel Simon
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316733	A1	19930902	WO 1993-CA62	19930216
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
CA 2061566	AA	19930821	CA 1992-2061566	19920220
CA 2061566	C	20020709		
AU 9334889	A1	19930913	AU 1993-34889	19930216
EP 626864	A1	19941207	EP 1993-903755	19930216
EP 626864	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07507054	T2	19950803	JP 1993-514408	19930216
HU 70440	A2	19951030	HU 1993-3283	19930216
NZ 299281	A	20001222	NZ 1993-299281	19930216
AT 244020	E	20030715	AT 1993-903755	19930216
PT 626864	T	20031128	PT 1993-903755	19930216
ES 2202311	T3	20040401	ES 1993-903755	19930216
CZ 290534	B6	20020814	CZ 1993-229	19930218
ZA 9301174	A	19930916	ZA 1993-1174	19930219
CA 2268476	AA	19980430	CA 1996-2268476	19961018
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
AU 9742732	A1	19980115	AU 1997-42732	19971020

HK 1005982	A1	20040305	HK 1998-105084		19980610
AU 768058	B2	20031127	AU 2000-42729		20000628
US 2003036525	A1	20030220	US 2002-234355		20020904
PRIORITY APPLN. INFO.:			CA 1992-2061566	A	19920220
			CA 1992-2061703	A	19920220
			WO 1993-CA62	A	19930216
			WO 1996-CA700	A	19961018
			US 1997-860696	A1	19970616
			AU 1997-42732	A3	19971020

AB Diseases of skin and exposed tissue are treated topically in humans with mixts. of **hyaluronic** acid and prostaglandin synthesis inhibitors, preferably **nonsteroidal** antiinflammatory agents. A formulation comprised Na **hyaluronate** 37.5, diclofenac Na 45, benzyl alc. 15, methoxypolyethylene glycol 300 g, and 1,200 mL water. The formulation was used for treatment of basal cell carcinoma.

L15 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1993:617437 CAPLUS
DOCUMENT NUMBER:	119:217437
TITLE:	Drugs containing **hyaluronic** acid for the topical treatment of skin diseases.
INVENTOR(S):	**Falk, Rudolf Edgar**; Asculai, Samuel Simon; Klein, Ehud Shmuel; Harper, David William; Hochman, David; Purschke, Don
PATENT ASSIGNEE(S):	Norpharmco Inc., Can.
SOURCE:	PCT Int. Appl., 106 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	24
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316732	A1	19930902	WO 1993-CA61	19930216
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
CA 2061703	AA	19930821	CA 1992-2061703	19920220
CA 2061703	C	20020702		
AU 9334888	A1	19930913	AU 1993-34888	19930216
EP 626863	A1	19941207	EP 1993-903754	19930216
EP 626863	B1	20010425		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07506812	T2	19950727	JP 1993-514407	19930216
IN 175918	A	19951028	IN 1993-CA94	19930216
HU 75089	A2	19970428	HU 1993-3282	19930216
PL 173211	B1	19980227	PL 1993-301149	19930216
NZ 299280	A	20001222	NZ 1993-299280	19930216
AT 200736	E	20010515	AT 1993-903754	19930216
ES 2156124	T3	20010616	ES 1993-903754	19930216
PT 626863	T	20010830	PT 1993-903754	19930216
CZ 290637	B6	20020911	CZ 1993-230	19930218
CN 1084064	A	19940323	CN 1993-103488	19930220
CN 1103219	B	20030319		
FI 9403789	A	19941003	FI 1994-3789	19940817
FI 113522	B1	20040514		
NO 9403044	A	19941019	NO 1994-3044	19940817
NO 312939	B1	20020722		
IN 179130	A	19970830	IN 1995-CA272	19950313
IN 182267	A	19990227	IN 1995-CA270	19950313
IN 182348	A	19990327	IN 1995-CA271	19950313
IN 178280	A	19970322	IN 1995-CA293	19950314
US 6140312	A	20001031	US 1995-466714	19950606
CA 2268476	AA	19980430	CA 1996-2268476	19961018
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 6475795	B1	20021105	US 1997-860696	19970616
AU 9742732	A1	19980115	AU 1997-42732	19971020

HK 1005983	A1	20010817	HK 1998-105085		19980610
GR 3036164	T3	20011031	GR 2001-401015		20010702
US 2003036525	A1	20030220	US 2002-234355		20020904
PRIORITY APPLN. INFO.:			CA 1992-2061703	A	19920220
			CA 1992-2061566	A	19920220
			IN 1993-CA94	A1	19930216
			WO 1993-CA61	A	19930216
			WO 1996-CA700	A	19961018
			US 1997-860696	A1	19970616

AB Compns. comprising **hyaluronic** acid and a **nonsteroidal** antiinflammatory agent or a neoplasm inhibitor are topical drugs for the treatment of skin diseases, especially **cancers**. A formulation comprised diclofenac sodium 45, Na **hyaluronate** 37.5, benzyl alc. 15, methoxypolyethylene glycol 300 g, and water to 1200 mL. The formulation was successful in the treatment of human basal cell carcinoma. **Hyaluronic** acid facilitates transport of the 2nd drug.

L15 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:51600 CAPLUS
DOCUMENT NUMBER: 116:51600
TITLE: **Hyaluronic** acid and derivatives for facilitating penetration of therapeutic agents in treatment of conditions and diseases
INVENTOR(S): **Falk, Rudolf Edgar**; Asculai, Samuel S.
PATENT ASSIGNEE(S): Norpharmco Inc., Can.
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 24
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9104058	A2	19910404	WO 1990-CA306	19900918
WO 9104058	A3	19910919		
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
CA 1340994	A1	20000516	CA 1989-612307	19890921
CA 2042034	AA	19910322	CA 1990-2042034	19900918
AU 9064330	A1	19910418	AU 1990-64330	19900918
EP 445255	A1	19910911	EP 1990-914108	19900918
EP 445255	B1	19951206		
EP 445255	B2	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
BR 9006924	A	19911210	BR 1990-6924	19900918
JP 04504579	T2	19920813	JP 1990-513204	19900918
JP 3256761	B2	20020212		
HU 64699	A2	19940228	HU 1990-7339	19900918
EP 656213	A1	19950607	EP 1995-100186	19900918
EP 656213	B1	20021113		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
AT 131068	E	19951215	AT 1990-914108	19900918
ES 2080837	T3	19960216	ES 1990-914108	19900918
RO 112812	B1	19980130	RO 1990-148511	19900918
RU 2146139	C1	20000310	RU 1990-4895848	19900918
AT 227587	E	20021115	AT 1995-100186	19900918
ES 2186693	T3	20030516	ES 1995-100186	19900918
IL 95745	A1	19990922	IL 1990-95745	19900919
CN 1051503	A	19910522	CN 1990-108840	19900921
CN 1101228	B	20030212		
ZA 9007564	A	19910828	ZA 1990-7564	19900921
IN 171745	A	19921226	IN 1990-CA821	19900921
NO 9101952	A	19910705	NO 1991-1952	19910521
US 6069135	A	20000530	US 1991-675908	19910703
AU 9352274	A1	19940303	AU 1993-52274	19931209
AU 674894	B2	19970116		
LT 3545	B	19951127	LT 1993-1582	19931210
US 5827834	A	19981027	US 1994-286263	19940805
US 5910489	A	19990608	US 1994-290848	19940819
US 5811410	A	19980922	US 1995-465335	19950605
US 5830882	A	19981103	US 1995-462615	19950605
US 5852002	A	19981222	US 1995-462147	19950605
US 5914314	A	19990622	US 1995-462614	19950605

US 5929048	A	19990727	US 1995-462148	19950605
US 5932560	A	19990803	US 1995-461124	19950605
US 5985850	A	19991116	US 1995-462154	19950605
US 6048844	A	20000411	US 1995-461565	19950605
US 5962433	A	19991005	US 1995-466778	19950606
US 6017900	A	20000125	US 1995-466775	19950606
US 6218373	B1	20010417	US 1995-467994	19950606
US 6194392	B1	20010227	US 1995-460978	19950807
CA 2268476	AA	19980430	CA 1996-2268476	19961018
AU 9672721	A1	19980515	AU 1996-72721	19961018
AU 739701	B2	20011018		
EP 952855	A1	19991103	EP 1996-934250	19961018
EP 952855	B1	20050727		
R: DE, FR, GB, IT, SE				
NZ 335259	A	20001222	NZ 1996-335259	19961018
ZA 9608847	A	19970527	ZA 1996-8847	19961022
US 5985851	A	19991116	US 1996-744852	19961118
AU 9714850	A1	19970522	AU 1997-14850	19970221
US 6475795	B1	20021105	US 1997-860696	19970616
HK 1005985	A1	20030214	HK 1998-105089	19980610
US 2003036525	A1	20030220	US 2002-234355	20020904
US 2004019011	A1	20040129	US 2003-628999	20030728

PRIORITY APPLN. INFO.:

CA 1989-612307	A	19890921
EP 1990-914108	A3	19900918
WO 1990-CA306	A	19900918
US 1991-675908	A1	19910703
CA 1992-2061566	A	19920220
CA 1992-2061703	A	19920220
US 1992-838674	B2	19920221
US 1992-838675	A2	19920221
US 1994-290848	A3	19940819
US 1994-290840	A3	19941027
WO 1996-CA700	A	19961018
US 1997-860696	A1	19970616
US 2000-547394	B1	20000411

AB **Hyaluronic** acid, i.e. including its salts, homologues, analogs, derivs., complexes, esters, or fragments of its subunits, is used in combination with therapeutic agents to facilitate the agent's penetration through the tissue or cell membrane to enhance the effectiveness and lower the dose and toxicity of the therapeutic agent, or to help to remove toxic substances from the target cell or tissue for treatment of diseases or conditions. The therapeutic agents are selected from a free radical scavenger, ascorbic acid, an anti-**cancer** agent, **chemotherapeutic** agent, anti-viral agent, etc. The diseases or conditions include **cancer**, herpes, canker sore, psoriasis, mononucleosis, post-menopause, control of fertility, renal failure, cardiac insufficiency, hypertension, edema, transplants, AIDS, detoxification, etc. Clin. studies are presented.

L22 ANSWER 1 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2002334400 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12077476
TITLE: Discernment of adipose versus nervous tissue: a novel adjunct solution in lipomyelomeningocele surgery.
AUTHOR: Patwardhan Ravish V; Tubbs R Shane; Leonard Robert J; Kelly David; Killingsworth Cheryl R; Rollins Dennis L; Smith William M; Ideker Raymond E; Oakes W Jerry
CORPORATE SOURCE: Division of Neurosurgery, The Children's Hospital of Alabama, Birmingham, AL, USA.. rpatwardhan@sport.rr.com
SOURCE: Pediatric neurosurgery, (2002 Jun) 36 (6) 314-9.
Journal code: 9114967. ISSN: 1016-2291.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020623
Last Updated on STN: 20020911
Entered Medline: 20020910

AB OBJECTIVE: To determine a solution capable of discerning adipose versus nervous tissue, to aid in surgical separation of the adipose tissue which appears to be visually indistinguishable from nervous tissue in lipomyelomeningoceles (LMMs). METHODS: The following solutes (in normal saline) were investigated, both at 25 and 37 degrees C: beta-carotene, **vitamin** D, **vitamin** E, lecithin, hydrogen peroxide, lipase, protease, **hyaluronidase**, partially purified collagenase, purified collagenase, trypsin, trypsin plus purified collagenase and non-solute-containing saline (control). Each solution was applied to a pediatric lipoma to determine gross effects over a period of approximately 30 min. If a solution appeared to affect the adipose tissue grossly, studies of functional in vivo sensory evoked and spontaneous potentials using that particular solution were conducted upon sheep spinal cord, nerve roots, dura and peripheral nerve. Additionally, histological studies were conducted to determine the effect of that solution upon adipose tissue, spinal cord, myelin, dura and nerve roots. RESULTS: Of all solutions investigated, partially purified collagenase type 1 (T1C; Lot M0M4322, Code CLS-1, Worthington Biochemical Corporation, Lakewood, N.J., USA) at 37 degrees C was the most successful in grossly altering the consistency and appearance of adipose tissue. This change was more apparent over 20-30 min following application of the solution to the adipose tissue. Solutions not containing T1C did not show appreciable results; purified collagenase plus trypsin did not appear comparable or superior to T1C. No significant histological or functional change was noted when comparing the spinal cord, nerve rootlets, myelin, dura or peripheral nerve from the T1C-treated group versus normal (untreated) control groups. CONCLUSION: T1C appears to be a potentially effective solution for application during LMM surgery in the acute setting, and such use of an adjunct solution may significantly aid in the safe surgical resection of LMMs. Pending further research, this technique may be applied for other indications which require discernment or alteration of adipose versus nervous tissue.

L22 ANSWER 2 OF 23 MEDLINE on STN
ACCESSION NUMBER: 1998331852 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9630735
TITLE: Ascorbic acid in the prevention and treatment of cancer.
AUTHOR: Head K A
CORPORATE SOURCE: Alternative Medicine Review. P.O. Box 25, Dover, ID 83825, USA.. kathi@thorne.com
SOURCE: Alternative medicine review : a journal of clinical therapeutic, (1998 Jun) 3 (3) 174-86. Ref: 63
Journal code: 9705340. ISSN: 1089-5159.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Consumer Health
ENTRY MONTH: 199807
ENTRY DATE: Entered STN: 19980811
Last Updated on STN: 19980811
Entered Medline: 19980728

AB Proposed mechanisms of action for ascorbic acid (ascorbate, **vitamin** C) in the prevention and treatment of cancer include

enhancement of the immune system, stimulation of collagen formation necessary for "walling off" tumors, inhibition of **hyaluronidase** which keeps the ground substance around the tumor intact and prevents metastasis, prevention of oncogenic viruses, correction of an ascorbate deficiency often seen in cancer patients, expedition of wound healing after cancer surgery, enhancement of the effect of certain **chemotherapy** drugs, reduction of the toxicity of other **chemotherapeutic** agents such as Adriamycin, prevention of free radical damage, and neutralization of carcinogenic substances. Scottish as well as Japanese studies have pointed to the potential benefit of high dose **vitamin** C for the treatment of "terminal" cancer. Mayo Clinic studies, however, have contradicted the Scottish and Japanese findings, resulting in accusations of methodological flaws from both sides. Numerous epidemiological studies have pointed to the importance of dietary and supplemental ascorbate in the prevention of various types of cancer including bladder, breast, cervical, colorectal, esophageal, lung, pancreatic, prostate, salivary gland, stomach, leukemia, and non-Hodgkin's lymphoma.

L22 ANSWER 3 OF 23 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2004:110793 BIOSIS
DOCUMENT NUMBER: PREV200400112259
TITLE: Andrology lab corner: Nurture vs nature: How can we optimize sperm quality?.
AUTHOR(S): Alvarez, Juan G. [Reprint Author]
CORPORATE SOURCE: Centro de Infertilidad Masculina, C/Fernando Macias, 8, 1C, 15004, La Coruna, Spain
jalvarez@androgen.es
SOURCE: Journal of Andrology, (September-October 2003) Vol. 24, No. 5, pp. 640-648. print.
ISSN: 0196-3635 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Feb 2004
Last Updated on STN: 25 Feb 2004

L22 ANSWER 4 OF 23 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2002189566 EMBASE
TITLE: Treatment options in extravasation injury: An experimental study in rats.
AUTHOR: Yilmaz M.; Demirdover C.; Mola F.
CORPORATE SOURCE: Dr. C. Demirdover, Dokuz Eylul Univ. Tip Fakultesi, Plast. Rekonstr. Cerrahi Anabilim, 35340 Inciralti, Izmir, Turkey.
cenkddr@mailcity.com
SOURCE: Plastic and Reconstructive Surgery, (2002) Vol. 109, No. 7, pp. 2418-2423.
Refs: 17
ISSN: 0032-1052 CODEN: PRSUAS
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 009 Surgery
013 Dermatology and Venereology
016 Cancer
037 Drug Literature Index
052 Toxicology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20020613
Last Updated on STN: 20020613

AB Local skin necrosis after extravasation of doxorubicin hydrochloride (Adriamycin), a widely used **chemotherapeutic** agent, is a common problem in cancer patients. Even though several treatment options have been proposed for extravasation injury, there is still controversy regarding the management of such lesions. The aim of this study was to compare the efficacy of saline infiltration, **vitamin** C infiltration, suction technique, and early surgical excision as a treatment in a rat extravasation model. The authors planned their study in two stages. In stage 1, the lowest effective dose of doxorubicin at which a homogeneous skin necrosis was formed and the method of administration were investigated. Intradermal and sub-pannicular injections were made for six rats, using six different concentrations of doxorubicin (0.33, 0.5, 0.66, 1.0, 1.33, and 1.5 mg/ml). In stage 1, the intradermal injection produced homogeneous and uniform tissue necrosis. In stage 2, the efficacy of saline infiltration (group 1), **vitamin** C infiltration (group 2), suction (group 3), suction and saline washout

(group 4), suction and **vitamin** C washout (group 5), and early surgical excision (group 6) was compared. The treatment options were applied 2 hours after doxorubicin injection. At the end of the seventh day, the presence and size of ulcers at the injection site were calculated. Fourteen days after injection, a histopathologic examination was performed for each treatment and control group. In groups 1 and 3, there was no statistically significant difference in the size of necrosis compared with the control groups. In groups 2, 4, and 5, the size of necrosis was smaller compared with the control groups, and this was statistically significant. Furthermore, in group 4 (suction and saline washout) and group 5 (suction and **vitamin** C washout), the calculated area of necrosis was smaller compared with other treatment groups, and this was statistically significant. The findings supported the assertion that suction and saline or **vitamin** C washout reduce necrotic tissue size in extravasation injury.

L22 ANSWER 5 OF 23 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 86082950 EMBASE
DOCUMENT NUMBER: 1986082950
TITLE: [Extravasation after use of antitumors drugs: Clinical experiences, procedures of prevention and therapy]. LESIVITA CUTANEA DA ANTIBLASTICI. ESPERIENZA CLINICA, MODALITA DI PREVENZIONE E TERAPIA.
AUTHOR: Villani C.; Doninelli M.; Giobbi L.; et al.
CORPORATE SOURCE: II Clinica Ostetrica e Ginecologica dell'Universita La Sapienza di Roma, Insegnamento di Ginecologia Oncologica, Roma, Italy
SOURCE: Patologia e Clinica Ostetrica e Ginecologica, (1985) Vol. 13, No. 4, pp. 267-272.
CODEN: PCOGBW
COUNTRY: Italy
DOCUMENT TYPE: Journal
FILE SEGMENT: 038 Adverse Reactions Titles
037 Drug Literature Index
010 Obstetrics and Gynecology
013 Dermatology and Venereology
LANGUAGE: Italian
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 911210
Last Updated on STN: 911210

L22 ANSWER 6 OF 23 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 86009829 EMBASE
DOCUMENT NUMBER: 1986009829
TITLE: [The treatment of local toxic reactions due to antitumour's agents].
IL TRATTAMENTO DELLE REAZIONI TOSSICHE LOCALI DA AGENTI ANTINEOPLASTICI.
AUTHOR: Pollera C.F.; Mazza D.; Nardi M.; et al.
CORPORATE SOURCE: Ispettorato di Sanita della Marina Militare, Roma, Italy
SOURCE: Annali di Medicina Navale, (1985) Vol. 90, No. 1, pp. 163-178.
CODEN: AMDNA4
COUNTRY: Italy
DOCUMENT TYPE: Journal
FILE SEGMENT: 038 Adverse Reactions Titles
037 Drug Literature Index
LANGUAGE: Italian
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 911210
Last Updated on STN: 911210

L22 ANSWER 7 OF 23 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 74128863 EMBASE
DOCUMENT NUMBER: 1974128863
TITLE: Changes in glycosaminoglycans of AH 130 ascites tumor after treatment with cyclophosphamide and **vitamin** A.
AUTHOR: Suematsu T.; Nakamura N.; Kamada T.; Abe H.
CORPORATE SOURCE: Dept. Med., Osaka Univ. Med. Sch., Osaka, Japan
SOURCE: Cancer Research, (1973) Vol. 33, No. 11, pp. 2862-2866.
CODEN: CNREA8
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index

016 Cancer
030 Pharmacology
029 Clinical Biochemistry
005 General Pathology and Pathological Anatomy

LANGUAGE: English

AB A large amount of glycosaminoglycans was found in the AH 130 ascites tumor cells and also in the ascites fluids. After combined administration of cyclophosphamide and **vitamin** A to the tumor bearing rats, a significant decrease was found in tumor glycosaminoglycans sensitive to lysosomal **hyaluronidase**, such as the nonsulfated glycosaminoglycans or chondroitin sulfate A and/or C. An increased release of the lysosomal enzymes into ascites was also consistently found. It is suggested that this reduction in tumor glycosaminoglycans reflects the synergistic effect of the combined administration of cyclophosphamide and **vitamin** A on the survival time of tumor bearing rats in this investigation.

L22 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:611948 CAPLUS
DOCUMENT NUMBER: 143:126813
TITLE: Treatment of ophthalmic conditions
PATENT ASSIGNEE(S): Osio Corp., USA; Osio Sancho, Alberto
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005062818	A2	20050714	WO 2004-US42660	20041217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: MX 2003-11987 A 20031219

AB Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably com. available and are not specifically designed for orthokeratol. The agents in the pharmaceutical compns. such as **hyaluronase** allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.

L22 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:570378 CAPLUS
DOCUMENT NUMBER: 143:103333
TITLE: Collagen matrix for soft tissue augmentation
INVENTOR(S): Freeman, Lynetta J.; Roweton, Susan; Walthall, Ben; Nguyen, Kien T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2005142161	A1	20050630	US 2003-748894	20031230
CA 2491788	AA	20050630	CA 2004-2491788	20041224
EP 1555035	A2	20050720	EP 2004-258168	20041229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2005193055	A2	20050721	JP 2005-202	20050104
PRIORITY APPLN. INFO.:			US 2003-748894	A 20031230

AB The present invention includes methods and materials for soft tissue implant formed from biol.-compatible polymeric matrixes. The matrixes may have pores sized for in-growth of soft tissue. The material may be utilized with collagen or other matrix materials. This material may be used in a method of reforming soft tissues by implanting the material within soft body tissues to modify soft tissue defects such as wrinkles or biopsy tissue defects and to reshape soft tissue. An in vivo evaluation of the com.-available Integra Life Sciences scaffold (without the silicone backing) as a subdermal defect filler was performed. Sheets and rolls (2 cm in length, 0.5 cm in diameter) of Integra were implanted subdermally over the ventral thoracic and abdominal regions of six pigs. Explant time periods for this study was 14, 42, and 180 days. The Integra material demonstrated acceptable biocompatibility in this study.

L22 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:471831 CAPLUS
DOCUMENT NUMBER: 143:1254
TITLE: Combinations and methods for treating neoplasms
INVENTOR(S): Yu, Baofa
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 765,060.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005118187	A1	20050602	US 2004-973798	20041025
US 2002044919	A1	20020418	US 2001-765060	20010117
US 6811788	B2	20041102		
PRIORITY APPLN. INFO.:			US 2000-177024P	P 20000119
			US 2001-765060	A2 20010117

AB Methods for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments, are provided. Also provided are combinations, and kits containing the combinations for effecting the therapy.

L22 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:300435 CAPLUS
DOCUMENT NUMBER: 142:373859
TITLE: Preparation of pyrimidine and pyridine derivatives useful as HMG-CoA reductase inhibitors
INVENTOR(S): Ahmad, Saleem; Robl, Jeffrey A.; Ngu, Khehyong
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030758	A1	20050407	WO 2004-US31212	20040922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				

SN, TD, TG

US 2005085497 A1 20050421 US 2004-946055 20040921
PRIORITY APPLN. INFO.: US 2003-505893P P 20030925
OTHER SOURCE(S): MARPAT 142:373859
AB Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkoxyalkyl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4 = H, (cyclo)alkyl, haloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetonide derivative I are HMG-CoA reductase inhibitors and are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis [no data].
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:161960 CAPLUS
DOCUMENT NUMBER: 142:266701
TITLE: Megalin-based delivery of therapeutic compounds to the brain and other tissues
INVENTOR(S): Zankel, Todd; Starr, Christopher M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 102 pp., Cont.-in-part of U.S. Ser. No. 600,862.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005042227	A1	20050224	US 2004-812849	20040330
US 2005026823	A1	20050203	US 2003-600862	20030620
WO 2005002515	A2	20050113	WO 2004-US19153	20040617
WO 2005002515	A3	20050714		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-600862 A2 20030620
US 2004-812849 A 20040330
AB The present invention is directed to a methods and compns. for receptor-mediated drug delivery, particularly across the blood-brain barrier. The present invention relates to the discovery that megalin ligands can be used as carriers or vectors for the delivery of active agents via transcytosis. RAP protein is such a ligand, which serves to increase the transport of therapeutic agents across the blood brain barrier and/or deliver agents to lysosomes of cells within and without the cental nervous system.

L22 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:160994 CAPLUS
DOCUMENT NUMBER: 142:254633
TITLE: Compositions and methods using heparin mimetics for inhibiting slit protein and glypican interactions, and use for promoting axonal regeneration and treating spinal cord injury
INVENTOR(S): Margolis, Richard U.
PATENT ASSIGNEE(S): New York University, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016285	A2	20050224	WO 2004-US26562	20040813

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-494906P P 20030813

AB The invention discloses a composition for inhibiting slit protein and glypican interactions which include an effective amount of a heparin mimetic. A pharmaceutical composition for inhibiting slit protein and glypican interactions includes an effective amount of a heparin mimetic and a pharmaceutical carrier. A composition for promoting axonal regeneration includes an effective amount of a heparin mimetic. A therapeutic composition for inhibiting slit protein and glypican interaction or promoting axonal regeneration includes an effective amount of a heparin mimetic. Also disclosed are various methods for inhibiting slit protein and glypican interaction, promoting axonal regeneration, and treating spinal cord injury.

L22 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:34719 CAPLUS

DOCUMENT NUMBER: 142:141213

TITLE: Delivery of therapeutic compounds to the brain and other tissues through lipoprotein receptor-related proteins for the treatment of CNS and lysosomal storage diseases

INVENTOR(S): Zankel, Todd; Starr, Christopher M.; Gabathuler, Reinhard

PATENT ASSIGNEE(S): Biomarin Pharmaceutical Inc., USA

SOURCE: PCT Int. Appl., 192 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002515	A2	20050113	WO 2004-US19153	20040617
WO 2005002515	A3	20050714		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005026823	A1	20050203	US 2003-600862	20030620
US 2005042227	A1	20050224	US 2004-812849	20040330

PRIORITY APPLN. INFO.: US 2003-600862 A 20030620
US 2004-812849 A 20040330

AB The present invention is directed to a methods and compns. for receptor mediated drug delivery, particularly across the blood-brain barrier. The present invention relates to the discovery that megalin ligands can be used as carriers or vectors for the delivery of active agents via transcytosis. An exemplary such ligand is RAP, which serves to increase the transport of therapeutic and /or diagnostic/investigational agents across the blood brain barrier and/or deliver agents to lysosomes of cells within and without the CNS. In particular embodiments, RAP fusion proteins containing human glucosidase (GAA), alpha-L-iduronidase (IDU) and glial-derived neurotrophic factor (GDNF) are tested for uptake or transcytosis in bovine brain capillary endothelial cell or fibroblast cell lines for the treatment lysosomal storage diseases.

L22 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1156506 CAPLUS
DOCUMENT NUMBER: 142:100372
TITLE: Antimicrobial silver formulations comprising silver and a silver resistance inhibitor
INVENTOR(S): Trotter, Patrick; Jampani, Hanuman; Mitscher, Lester; Pillai, Segaran
PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112805	A1	20041229	WO 2004-GB2631	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2402880	A1	20041222	GB 2003-14453	20030620
PRIORITY APPLN. INFO.:			GB 2003-14453 A	20030620
			US 2003-491990P P	20030804

AB An antimicrobial composition comprising silver and at least one compound which interacts with a microbial cell wall to inhibit microbial silver resistance. The resistance inhibitors include mols. that can promote the transport of silver across the cell wall, and/or disrupt the cell wall to allow silver into the cell, and/or disrupt ion pump mechanisms in the cell wall for removing silver from the cell. Inhibitor compds. include fusaric acid, tocopherol, resveratrol, and myristic acid. Also provided are wound dressings comprising the inventive compns.
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:754417 CAPLUS
DOCUMENT NUMBER: 141:256532
TITLE: Soluble derivatives of human neutral **hyaluronidase** and their secretory manufacture for use in therapeutic modulation of glycosaminoglycan metabolism
INVENTOR(S): Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I.
PATENT ASSIGNEE(S): Deliatroph Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078140	A2	20040916	WO 2004-US6656	20040305
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004268425 A1 20041230 US 2004-795095 20040305
PRIORITY APPLN. INFO.: US 2003-452360P P 20030305

AB A variant of human neutral active **hyaluronidase** with improved solubility is constructed and a cDNA encoding it is cloned for manufacture of the enzyme for use in the the treatment of glycosaminoglycan-associated pathologies. This variant of the enzyme lacks its hydrophobic C-terminal domain including the GPI anchor to improve solubility and increase yields of secreted activity. Minimally active domains of the enzyme, including asparagine-linked glycosidation required for a functional enzyme are identified. Secretory manufacture of the enzyme and the use of leader peptides that increase the efficiency of secretion of the enzyme are also described. The signal and leader peptide of the enzyme is unusually long and may play a role in limiting secretion by promoting aggregation. Replacing it with the signal peptide of the mouse Ig κ chain increased yields of secreted enzyme by .apprx.6-fold. Modified forms of the enzyme, e.g. sialylated and PEGylated, with increased stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes are described. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

L22 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:354980 CAPLUS
DOCUMENT NUMBER: 140:363010
TITLE: Taxanes covalently bounded to **hyaluronic** acid or **hyaluronic** acid derivatives
INVENTOR(S): De Luca, Gilda; Marini Bettolo, Rinaldo; Migneco, Luisa Maria
PATENT ASSIGNEE(S): Fidia Farmaceutici S.P.A., Italy
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035629	A2	20040429	WO 2003-EP11239	20031010
WO 2004035629	A3	20040624		
WO 2004035629	C1	20050609		
WO 2004035629	C2	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502531	AA	20040429	CA 2003-2502531	20031010
EP 1560854	A2	20050810	EP 2003-748126	20031010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015431	A	20050816	BR 2003-15431	20031010
PRIORITY APPLN. INFO.:			IT 2002-PD271 A	20021018
			WO 2003-EP11239 W	20031010

AB Water-soluble taxanes covalently bounded to **hyaluronic** acid or **hyaluronic** acid derivs., and in particular to paclitaxel and docetaxel, are useful for the preparation of pharmaceutical compns. to be used in the field of oncol., in the treatment of autoimmune disorders and of restenosis. The invention also relates to the process for preparing taxanes covalently bounded to **hyaluronic** acid or **hyaluronic** acid derivs. by direct synthesis between mols. of **hyaluronic** acid and of taxane or by indirect synthesis by the introduction of a spacer between the **hyaluronic** acid or **hyaluronic** acid derivative and the taxane. Ester derivative of HA covalently bound to paclitaxel with 16% of esterification of the carboxyl was prepared Effect of the ester derivative of HA with paclitaxel in nude mouse after implantation of human ovary adenocarcinoma cells, was studied. The control animals developed adenocarcinoma of the ovary and died between 15 and 75th days after inoculation of the cancer cells. On the 92nd day after intervention, none of the animals that had received pharmacol. treatment with paclitaxel or the **hyaluronate** ester had died.

L22 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:80180 CAPLUS
DOCUMENT NUMBER: 140:133849
TITLE: Particles coated on the surface with **hyaluronan** or one of its derivatives, and their use as biological vectors
INVENTOR(S): Dellacherie, Edith; Leonard, Michele; Gref, Ruxandra; Netter, Patrick; Payan, Elisabeth
PATENT ASSIGNEE(S): Centre National de la Recherche Scientifique CNRS, Fr.
SOURCE: Fr. Demande, 20 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2842737	A1	20040130	FR 2002-9436	20020725
CA 2493470	AA	20040219	CA 2003-2493470	20030721
WO 2004014347	A1	20040219	WO 2003-FR2299	20030721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1524970	A1	20050427	EP 2003-769524	20030721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: FR 2002-9436 A 20020725
WO 2003-FR2299 W 20030721

AB Particles with cores comprising an organosol. biodegradable polymer coated at least partially on the surface, with **hyaluronan** or one of its derives. are used as biol. vectors for active materials. Polylactide particles were coated with C18 alkyl derivs. of sodium **hyaluronate** . Effects of the particles on the proliferation of cultured chondrocytes was studied.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:989927 CAPLUS
DOCUMENT NUMBER: 140:19891
TITLE: Compositions for treatment of diseases arising from secretion of mast cell biochemicals
INVENTOR(S): Theoharides, Theoharis C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No.773,576.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003232100	A1	20031218	US 2003-439301	20030516
US 6689748	B1	20040210	US 1998-56707	19980408

PRIORITY APPLN. INFO.: US 1998-56707 A3 19980408
US 2001-773576 A2 20010202

AB Compns. for treatment of diseases arising from products secreted by activated tissue mast cells, composed of, as active ingredients, unprocessed olive kernel (pit) extract that increases absorption of these compns. in various routes of administration, and one or more of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, a hexosamine sulfate such as D-glucosamine sulfate, a flavonoid such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, a CRH antagonist, caffeine, fragments of myelin basic protein, rutin, polyunsatd. fatty acids, Bitter

Willow Extract and a polyamine.

L22 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:173470 CAPLUS
DOCUMENT NUMBER: 138:198677
TITLE: Use of **hyaluronan** as a protective agent in **chemotherapy** for improved therapeutic protocols
INVENTOR(S): Brown, Tracey Jean; Fox, Richard Mark
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018062	A1	20030306	WO 2002-AU1160	20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2458856	AA	20030306	CA 2002-2458856	20020827
EP 1427447	A1	20040616	EP 2002-759888	20020827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505540	T2	20050224	JP 2003-522577	20020827
US 2005042303	A1	20050224	US 2004-479934	20040930

PRIORITY APPLN. INFO.:
AU 2001-7302 A 20010827
AU 2001-9504 A 20011213
WO 2002-AU1160 W 20020827

AB The invention relates to the field of **chemotherapy** of diseases, e.g. cell proliferation disorders including cancer. In particular, the invention discloses the use of **hyaluronan** (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a **chemotherapeutic** agent to facilitate the prolonged administration of a dose of the **chemotherapeutic** agent to be administered to a subject. Owing to the protective effects of the HA, the dose of **chemotherapeutic** agent may be substantially higher than a generally accepted ED, which would otherwise be expected to cause unacceptable side effects in the subject.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:711276 CAPLUS
DOCUMENT NUMBER: 137:237738
TITLE: Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
INVENTOR(S): Modi, Pankaj
PATENT ASSIGNEE(S): Generex Pharmaceuticals Incorporated, Can.
SOURCE: U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 519,285.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6451286	B1	20020917	US 2000-574504	20000519
US 6436367	B1	20020820	US 1999-251464	19990217
US 6312665	B1	20011106	US 1999-386284	19990831
US 6375975	B1	20020423	US 2000-519285	20000306
CA 2410065	AA	20011122	CA 2001-2410065	20010507
WO 2001087268	A1	20011122	WO 2001-CA661	20010507

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1296648	A1	20030402	EP 2001-931281	20010507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 522524	A	20030725	NZ 2001-522524	20010507
JP 2003533469	T2	20031111	JP 2001-583737	20010507
US 2003035831	A1	20030220	US 2002-222699	20020816
US 6849263	B2	20050201		
US 2003157029	A1	20030821	US 2002-222240	20020816
PRIORITY APPLN. INFO.:			US 1998-113239P	P 19981221
			US 1999-251464	A2 19990217
			US 1999-386284	A2 19990831
			US 2000-519285	A2 20000306
			US 2000-574504	A 20000519
			WO 2001-CA661	W 20010507

AB Pharmaceutical compns. comprising a macromol. pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compds. Micelle size ranges between about 1 and 10 nm. Methods for making and using the compns. are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth. For example, to 1000 mg of powdered insulin dissolved in 10 mL of distilled water were added 50 mg sodium lauryl sulfate, 36 mg deoxycholate, 50 mg trihydroxyoxocholanylglycine (sodium glycocholate) and 20 mg dibasic Na phosphate followed by 250 mg glycerin, 40 mg m-cresol and 40 mg phenol. The solution (1 mL) was pipetted into 10 mL capacity glass vials, the vials were charged with HFA-134a propellant and stored at room temperature The oral insulin composition prepared (70 unit dose) performed much better in diabetic patients than hypoglycemic Metformin tablets in controlling glucose levels.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:151474 CAPLUS
DOCUMENT NUMBER: 136:205405
TITLE: Mixed micellar drug delivery system and method of preparation
INVENTOR(S): Modi, Pankaj
PATENT ASSIGNEE(S): Generex Pharmaceuticals Incorporated, Can.
SOURCE: U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 386,285. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6350458	B1	20020226	US 2000-543988	20000406
US 6017545	A	20000125	US 1998-21114	19980210
US 6231882	B1	20010515	US 1998-216733	19981221
US 6221378	B1	20010424	US 1999-386285	19990831
PRIORITY APPLN. INFO.:			US 1998-21114	A2 19980210
			US 1998-216733	A2 19981221
			US 1999-386285	A2 19990831

AB Pharmaceutical compns. comprising a macromol. pharmaceutical agent in micellar form are disclosed. The micelles are formed from an alkali metal alkyl sulfate, and at least one addnl. micelle-forming compound as described in the specification. An alkali metal salicylate and a pharmaceutically acceptable edetate are also included in the composition Micelle size ranges between about 1 and 10 nm. Methods for making and using the compns. are also disclosed. A buffer solution was prepared using 0.5 g sodium lauryl sulfate, 0.5 g sodium salicylate, and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to 16 mg (400 units) of insulin and mixed, to form micellar insulin. Sep., 100 mg of powdered Phosphatidylcholine-H was added to a glass beaker and to this powder was added 10 mL 50% ethanol. This solution was then added to the above buffer

solution, to give a 30 units/mg insulin solution, with vigorous mixing to form a mixed micellar solution To this was added 0.6 mL of sodium **hyaluronate** and 0.2 mL of 2% menthol solution containing 3% sorbitol. Type II diabetic human volunteers took the micellar insulin orally. The oral insulin at a dosage of three times higher than the injected level, was comparable to the injected insulin.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:292567 CAPLUS
DOCUMENT NUMBER: 130:329203
TITLE: Drug composition with controlled drug release rate comprising **hyaluronate** and biodegradable polymers
INVENTOR(S): Suzuki, Makoto; Ishigaki, Kenji; Okada, Minoru; Ono, Kenji; Kasai, Shuichi; Imamori, Katsumi
PATENT ASSIGNEE(S): SSP Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 913149	A1	19990506	EP 1998-119415	19981014
EP 913149	B1	20050309		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 11130697	A2	19990518	JP 1997-294008	19971027
TW 520292	B	20030211	TW 1998-87116892	19981012
US 6375988	B1	20020423	US 1998-172270	19981014
CA 2251281	AA	19990427	CA 1998-2251281	19981020
CN 1220874	A	19990630	CN 1998-122614	19981027
HK 1019142	A1	20040716	HK 1999-104382	19991007
PRIORITY APPLN. INFO.:			JP 1997-294008 A	19971027

AB A drug composition with a controlled drug release rate is disclosed. The drug composition comprises (a) a biodegradable, biocompatible high-mol. substance and/or polyvalent metal ions or polyvalent metal ion source, and (b) **hyaluronic** acid or a salt thereof; and a drug incorporated as an ingredient (c) in said matrix. The drug composition has biodegradability and biocompatibility, permits easy control of a release rate of the drug, and can persistently exhibit its pharmacol. effect over a long time. A solution of 1% sodium **hyaluronate** (I)was added to 200 mg medium-chain fatty acid triglyceride and the mixture was stirred followed by addition of 50% aqueous calcium chloride solution The microspheres thus obtained were separated, washed, and dried. The microspheres had an average particle size of 78.4 μm and I content of 78.1%.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT